BeyondSpring Inc. Share-based Payment Arrangement, Expense
BeyondSpring Inc. (BYSI) reported Share-based Payment Arrangement, Expense of $496 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-03-25
- BeyondSpring Inc. share-based payment arrangement, expense for the quarter ending 2021-12-31 was -$2.14M, a 201.23% decline year-over-year.
- BeyondSpring Inc. share-based payment arrangement, expense for the quarter ending 2021-09-30 was $1.74M, a 1.91% decline year-over-year.
- BeyondSpring Inc. share-based payment arrangement, expense for the quarter ending 2021-06-30 was $2.43M, a 190.19% increase year-over-year.
- BeyondSpring Inc. share-based payment arrangement, expense for the quarter ending 2021-03-31 was $1.12M, a 67.67% decline year-over-year.
- BeyondSpring Inc. share-based payment arrangement, expense for fiscal 2025 was $496.00, a 75.96% decline from fiscal 2024.
- BeyondSpring Inc. share-based payment arrangement, expense for fiscal 2024 was $2.06K, a 272.38% increase from fiscal 2023.
- BeyondSpring Inc. share-based payment arrangement, expense for fiscal 2023 was $554.00.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $496.00 10-K · filed 2026-03-25 | ||||
| 2024-12-31 | $2.06K 10-K · filed 2026-03-25 | ||||
| 2023-12-31 | $554.00 10-K · filed 2025-03-27 | ||||
| 2022-12-31 | $1.58M 20-F · filed 2023-04-18 | ||||
| 2021-12-31 | -$2.14M derived: 20-F 12 month − 6-K 9 month · filed 2023-04-18 | -$396.00K derived: sum of 2 quarters · filed 2023-04-18 | $2.03M derived: sum of 3 quarters · filed 2023-04-18 | $3.15M 20-F · filed 2023-04-18 | |
| 2021-09-30 | $1.74M 6-K · filed 2021-12-30 | $4.17M derived: sum of 2 quarters · filed 2021-12-30 | $5.29M 6-K · filed 2021-12-30 | $7.40M derived: sum of 4 quarters · filed 2023-04-18 | |
| 2021-06-30 | $2.43M 6-K · filed 2021-09-10 | $3.55M 6-K · filed 2021-09-10 | $5.66M derived: sum of 3 quarters · filed 2023-04-18 | $7.44M derived: sum of 4 quarters · filed 2023-04-18 | |
| 2021-03-31 | $1.12M 6-K · filed 2021-06-16 | $3.23M derived: sum of 2 quarters · filed 2023-04-18 | $5.01M derived: sum of 3 quarters · filed 2023-04-18 | $5.85M derived: sum of 4 quarters · filed 2023-04-18 | |
| 2020-12-31 | $2.11M derived: 20-F 12 month − 6-K 9 month · filed 2023-04-18 | $3.89M derived: sum of 2 quarters · filed 2023-04-18 | $4.72M derived: sum of 3 quarters · filed 2023-04-18 | $8.19M 20-F · filed 2023-04-18 | |
| 2020-09-30 | $1.78M 6-K · filed 2021-12-30 | $2.61M derived: sum of 2 quarters · filed 2021-12-30 | $6.08M 6-K · filed 2021-12-30 | $6.43M derived: sum of 4 quarters · filed 2022-04-14 | |
| 2020-06-30 | $836.00K 6-K · filed 2021-09-10 | $4.31M 6-K · filed 2021-09-10 | $4.66M derived: sum of 3 quarters · filed 2022-04-14 | $5.12M derived: sum of 4 quarters · filed 2022-04-14 | |
| 2020-03-31 | $3.47M 6-K · filed 2021-06-16 | $3.82M derived: sum of 2 quarters · filed 2022-04-14 | $4.28M derived: sum of 3 quarters · filed 2022-04-14 | $5.20M derived: sum of 4 quarters · filed 2022-04-14 | |
| 2019-12-31 | $351.00K derived: 20-F 12 month − 6-K 9 month · filed 2022-04-14 | $813.00K derived: sum of 2 quarters · filed 2022-04-14 | $1.73M derived: sum of 3 quarters · filed 2022-04-14 | $2.10M 20-F · filed 2022-04-14 | |
| 2019-09-30 | $462.00K 6-K · filed 2020-11-17 | $1.38M derived: sum of 2 quarters · filed 2020-11-17 | $1.75M 6-K · filed 2020-11-17 | $2.27M derived: sum of 4 quarters · filed 2021-04-30 | |
| 2019-06-30 | $916.00K 6-K · filed 2020-09-03 | $1.29M 6-K · filed 2020-09-03 | $1.81M derived: sum of 3 quarters · filed 2021-04-30 | $2.65M derived: sum of 4 quarters · filed 2021-04-30 | |
| 2019-03-31 | $371.00K 6-K · filed 2020-06-11 | $890.00K derived: sum of 2 quarters · filed 2021-04-30 | $1.74M derived: sum of 3 quarters · filed 2021-04-30 | $2.73M derived: sum of 4 quarters · filed 2021-04-30 | |
| 2018-12-31 | $519.00K derived: 20-F 12 month − 6-K 9 month · filed 2021-04-30 | $1.37M derived: sum of 2 quarters · filed 2021-04-30 | $2.36M derived: sum of 3 quarters · filed 2021-04-30 | $6.56M 20-F · filed 2021-04-30 | |
| 2018-09-30 | $848.00K 6-K · filed 2019-12-18 | $1.84M derived: sum of 2 quarters · filed 2019-12-18 | $6.04M 6-K · filed 2019-12-18 | $9.86M derived: sum of 4 quarters · filed 2020-04-30 | |
| 2018-06-30 | $992.00K 6-K · filed 2019-09-18 | $5.19M 6-K · filed 2019-09-18 | $9.01M derived: sum of 3 quarters · filed 2020-04-30 | $19.12M derived: sum of 4 quarters · filed 2020-04-30 | |
| 2018-03-31 | $4.20M 6-K · filed 2019-07-10 | $8.02M derived: sum of 2 quarters · filed 2020-04-30 | $18.13M derived: sum of 3 quarters · filed 2020-04-30 | $26.88M derived: sum of 4 quarters · filed 2020-04-30 | |
| 2017-12-31 | $3.82M derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | $13.93M derived: sum of 2 quarters · filed 2020-04-30 | $22.68M derived: sum of 3 quarters · filed 2020-04-30 | $22.68M 20-F · filed 2020-04-30 | |
| 2017-09-30 | $10.11M 6-K · filed 2017-11-09 | $18.86M derived: sum of 2 quarters · filed 2018-10-23 | $18.86M 6-K · filed 2017-11-09 | ||
| 2017-06-30 | $8.76M 6-K · filed 2018-10-23 | $8.76M 6-K · filed 2018-10-23 | $8.76K 6-K · filed 2017-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |